Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 22

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Familial hypertriglyceridaemia+1

Recruiting

Study of ISIS 678354 for Patients with Familial Chylomicronemia Syndrome Previously Treated with Volanesorsen

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Type 1 diabetes mellitus

Recruiting

Study on Anti-T Lymphocyte Immunoglobulin for Children and Young Adults with Recent Type 1 Diabetes to Preserve Beta Cell Function

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
  • Sponsor:Institute For Clinical And Experimental Medicine

Glycogen storage disease type II

Recruiting

Study on the Effects of Avalglucosidase Alfa Enzyme Replacement Therapy in Patients with Pompe Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Rigshospitalet

Glycogen storage disease type II

Recruiting

Study on Gene Therapy with AAV9.LAMP2B for Male Patients with Danon Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Rocket Pharmaceuticals Inc.

Type 1 diabetes mellitus

Recruiting

Study on the Effect of Influenza Vaccine on Preserving Beta Cell Function in Early Type 1 Diabetes Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Sponsor:Region Midtjylland

PIK3CA related overgrowth spectrum

Recruiting

Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Alpelisib
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Diabetic neuropathy

Recruiting

Study of Incobotulinumtoxin-A Injections for Diabetic Neuropathic Pain in the Lower Limbs

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Rigshospitalet

Diabetic foot infection

Recruiting

Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Micurx Pharmaceuticals Inc.

Osteoporosis

Recruiting

Study on Zoledronic Acid Following Denosumab for Osteoporosis Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:Region Midtjylland

Alpha-1 antitrypsin deficiency

Recruiting

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Hepato-lenticular degeneration

Recruiting

Study on the Safety and Effects of UX701 Gene Therapy for Adults with Wilson Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Glucose tolerance impaired

Recruiting

Study of Semaglutide for Treating Prediabetes in Women with Previous Gestational Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:UZ Leuven

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.